Bivalent ligand approach on 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine: synthesis and binding affinities for 5-HT(7) and 5-HT(1A) receptors. 2007

Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
Università degli Studi di Bari, Dipartimento Farmaco-Chimico, via Orabona, 4, Bari, Italy. leopoldo@farmchim.uniba.it

We here report on the synthesis and binding properties at 5-HT(7) and 5-HT(1A) receptors of ligands 3-12, that were designed according to the 'bivalent ligand' approach. Two moieties of the 5-HT(7)/5-HT(1A) ligand 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine (1) were linked through their 3-methoxy substituent by polymethylene chains of variable length, with the aim to increase the affinity for 5-HT(7) receptor and the selectivity over 5-HT(1A) receptors. In the best cases, the dimers showed affinities for 5-HT(7) receptors as high as the monomer with no improvement in selectivity. Some dimers displayed 5-HT(1A) receptor affinities slightly higher than monomer 1.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D044282 Receptor, Serotonin, 5-HT1A A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN RECEPTOR AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION. Serotonin 1A Receptor,5-HT(1A) Receptor,5-HT1A Receptor,5-Hydroxytryptamine 1A Receptor,5-Hydroxytryptamine 1A Receptors,Receptor, 5-Hydroxytryptamine 1A,Serotonin Receptor, 5-HT1A,Serotonin, 5-HT1a Receptor,1A Receptor, 5-Hydroxytryptamine,1A Receptors, 5-Hydroxytryptamine,5 HT1A Receptor,5 Hydroxytryptamine 1A Receptor,5 Hydroxytryptamine 1A Receptors,5-HT1A Serotonin Receptor,5-HT1a Receptor Serotonin,Receptor Serotonin, 5-HT1a,Receptor, 5 Hydroxytryptamine 1A,Receptor, 5-HT1A,Receptor, 5-HT1A Serotonin,Receptor, Serotonin 1A,Receptors, 5-Hydroxytryptamine 1A,Serotonin Receptor, 5 HT1A,Serotonin, 5 HT1a Receptor

Related Publications

Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
August 2011, Bioorganic & medicinal chemistry,
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
September 2007, Archiv der Pharmazie,
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
May 1996, The Journal of pharmacology and experimental therapeutics,
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
May 1994, Journal of medicinal chemistry,
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
March 1960, Antibiotic medicine & clinical therapy (New York, NY),
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
June 1987, European journal of pharmacology,
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
December 1991, Farmaco (Societa chimica italiana : 1989),
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
December 1994, Synapse (New York, N.Y.),
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
October 2014, European journal of medicinal chemistry,
Marcello Leopoldo, and Enza Lacivita, and Nicola A Colabufo, and Mauro Niso, and Francesco Berardi, and Roberto Perrone
August 2008, Acta crystallographica. Section E, Structure reports online,
Copied contents to your clipboard!